CNBX Pharmaceuticals (CNBX) Long-Term Debt Issuances (2016 - 2025)
CNBX Pharmaceuticals (CNBX) has disclosed Long-Term Debt Issuances for 7 consecutive years, with $30008.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Long-Term Debt Issuances rose 2281.59% year-over-year to $30008.0, compared with a TTM value of $140008.0 through Nov 2025, up 330.54%, and an annual FY2025 reading of $160000.0, up 481.56% over the prior year.
- Long-Term Debt Issuances was $30008.0 for Q3 2025 at CNBX Pharmaceuticals, down from $80000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $1.2 million in Q2 2021 and bottomed at $1259.0 in Q2 2024.
- Average Long-Term Debt Issuances over 5 years is $165238.4, with a median of $30004.0 recorded in 2024.
- The sharpest move saw Long-Term Debt Issuances tumbled 98.06% in 2024, then soared 2281.59% in 2025.
- Year by year, Long-Term Debt Issuances stood at $1.2 million in 2021, then tumbled by 88.01% to $149858.0 in 2022, then plummeted by 83.32% to $24993.0 in 2023, then increased by 20.03% to $30000.0 in 2024, then increased by 0.03% to $30008.0 in 2025.
- Business Quant data shows Long-Term Debt Issuances for CNBX at $30008.0 in Q3 2025, $80000.0 in Q1 2025, and $30000.0 in Q4 2024.